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Abstract Eldecalcitol reduces the risk of vertebral frac-
tures in comparison to alfacalcidol in osteoporotic patients
under vitamin D repletion. The aim of this study was to
evaluate the effects of eldecalcitol on the spinal location of
incident vertebral fractures, the severity of the fractures,
and the changes in health-related quality of life (HRQOL)
compared with those of alfacalcidol. The post hoc analysis
has been performed on the data from the three-year, dou-
ble-blind, randomized, head-to-head clinical trial of elde-
calcitol versus alfacalcidol conducted in Japan. A total of
1054 patients were enrolled and randomized to take
0.75 lg eldecalcitol or 1.0 lg alfacalcidol daily for
3 years. The incidence of vertebral fractures was re-eval-
uated based on the location on the spine (upper T4–T10;
lower T11–L4). The severity of vertebral fractures was
determined by the semi-quantitative method, and the
change in HRQOL was analyzed by using the Medical
Outcomes Study Short Form 36-item questionnaire. The
incidence of vertebral fracture at the lower spine was less
in the eldecalcitol group than in the alfacalcidol group
(p = 0.029). The incidence of severe vertebral fracture
(Grade 3) was 3.8 % in the eldecalcitol group and 6.7 % in
the alfacalcidol group, demonstrated a significant differ-
ence between the 2 groups (p = 0.036). Both eldecalcitol
and alfacalcidol improved HRQOL in osteoporotic
patients. Although no significant differences in each
HRQOL scores were observed between eldecalcitol and
alfacalcidol during the observational period, overall
improvement from baseline of HRQOL scores were clearly
observed in the eldecalcitol group. In conclusion, the
incidences of lower spinal vertebral fractures and severe
vertebral fractures were reduced further by eldecalcitol
compared to alfacalcidol in the 3-year clinical trial. Daily
treatment with eldecalcitol is effective in improving
HRQOL, possibly owing to the reduced risk of lower spinal
vertebral fractures and/or severe vertebral fractures.
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Introduction
With the rapid increase in the elderly population, osteo-
porosis and osteoporosis-related fractures have become
major concerns in many countries. In patients with a high
fracture risk, appropriate treatment is needed with drugs
that have shown definite evidence of their fracture
prevention effect. Postmenopausal osteoporosis is induced
by accelerated bone resorption and a systemic calcium
imbalance due to estrogen deficiency induced by menopause.
H. Hagino (&)
School of Health Science, Tottori University, 86 Nishi-Cho,
Yonago, Tottori 683-8503, Japan
e-mail: hagino@med.tottori-u.ac.jp
T. Takano
Chugai Pharmaceutical Co. Ltd, Tokyo 103-8324, Japan
M. Fukunaga
Kawasaki Medical School, Okayama 701-0192, Japan
M. Shiraki
Research Institute and Practice for Involutional Diseases,
Nagano 399-8101, Japan
T. Nakamura
University of Occupational and Environmental Health,
Fukuoka 807-8555, Japan
T. Matsumoto
University of Tokushima Graduate School of Medical Sciences,
Tokushima 770-8503, Japan
123
J Bone Miner Metab (2013) 31:183–189
DOI 10.1007/s00774-012-0397-6
Moreover, deficiency or insufficiency of vitamin D seems
a common health problem in elderly people, especially in
patients with fragility fractures [1]. Active vitamin D,
calcitriol, and its prodrug alfacalcidol are widely used in
the treatment of calcium- and bone-related diseases
including osteoporosis. Several studies have examined
their effects on the incidence of fragility fractures in
osteoporotic patients, and some studies demonstrated that
treatment with calcitriol or alfacalcidol resulted in a sig-
nificant reduction in incidence of vertebral fractures
compared with control [2–4].
Eldecalcitol, a vitamin D analog that has a hydroxy-
propyloxy substituent at the 2b-position of 1,25-di-
hydroxyvitamin D3, is available in Japan for the treatment
of osteoporosis at a dosage of 0.75 lg/day. In a ran-
domized, double-blind comparison with alfacalcidol
(1.0 lg/day), eldecalcitol (0.75 lg/day) produced signifi-
cantly greater reductions in biomarkers of both bone
formation and bone resorption among vitamin-D-sufficient
osteoporotic patients [5]. In that trial, eldecalcitol treat-
ment was associated with an increase in bone mineral
density and had a positive effect on femoral biomechan-
ical properties, showing significant differences from the
patients who received alfacalcidol [6]. Concerning frac-
ture prevention, in comparison with alfacalcidol, elde-
calcitol significantly reduced the 3-year incidence of
vertebral fractures, with an absolute risk reduction of
4.1 % over this period, representing a relative risk
reduction of 26 %. No significant difference in the inci-
dence of total non-vertebral fractures was observed
between the eldecalcitol and alfacalcidol groups; how-
ever, the incidence of fractures in the alfacalcidol group
at 36 months tended to be lower at the 3 major non-
vertebral sites (humerus, wrist, and hip).
Fracture prevention is the main aim in the treatment of
osteoporosis; however, health-related quality of life
(HRQOL) is also an important consideration in its man-
agement. The morbidity of vertebral fractures in patients
with osteoporosis varies from mild cases, with only slight
pain, to severe and multiple fracture cases with acute pain
and many recurrences, and this depends on the location of
the vertebral fracture on the spine. It is reported that there
is a difference in HRQOL of patients depending on the
spinal location of the vertebral fracture [7, 8]. Therefore,
the location of the vertebral fracture is an important factor
relating to the impairment of HRQOL. However to the best
of our knowledge, there is no report on the effect of anti-
osteoporosis drugs with respect to the vertebral fracture
location and its relation to HRQOL. Accordingly, the
purpose of the present study was to evaluate the effects of
eldecalcitol versus alfacalcidol on the location of incident
vertebral fractures and on the severity of the fractures, as
well as the changes in HRQOL in each group.
Materials and methods
Study design
This was a post hoc analysis of a 3-year, phase III, randomized,
active comparator, double-blind, head-to-head trial of the
effect of eldecalcitol versus alfacalcidol on reduction in inci-
dence of vertebral fractures. Details of the design and the
results of the primary endpoint in the study have been pub-
lished previously [5]. In that phase III trial, the primary end-
point was the incidence of non-traumatic new vertebral
fractures, while other endpoints were the percent change in
lumbar spine BMD and total hip BMD, percent change in bone
turnover markers, and incidence of non-vertebral fractures. In
the current study we re-assessed the incidence of vertebral
fractures based on their location on the spine. We also analyzed
the change in HRQOL during the 3-year observational period.
Patients
A total of 1054 patients (1030 females and 24 males, all
Japanese) aged from 46 to 92 years (mean 72.1 years) from
52 centers in Japan were enrolled from September 2004 to
August 2005. Patients were randomized to take 0.75 lg
eldecalcitol or 1.0 lg alfacalcidol once a day for 3 years
(36 months) [5]. Patients with serum 25(OH)D values
lower than 20 ng/mL at baseline were given an oral vitamin
D3 supplement (400 IU) once a day. Patients with lumbar
spine or total hip BMD T-score below -1.7 were enrolled if
they had 1 to 5 vertebral fractures. Patients without verte-
bral fractures were also enrolled if their lumbar spine or
total hip BMD T-score was below -2.6 and they were aged
70 years or older, or if their T-score was below -3.4 and
they were aged less than 70 years. Patients with metabolic
bone disease such as primary hyperparathyroidism, Cush-
ing’s syndrome, premature menopause, poorly controlled
diabetes mellitus (HbA1c over 9 %), or other causes of
secondary osteoporosis or patients who had a history of
urolithiasis were excluded from the study. Patients were
also excluded if they had taken any oral bisphosphonates
within 6 months before entry or for more than 2 weeks
during the period 6 to 12 months before entry, or intrave-
nous bisphosphonates at any time; had taken glucocorti-
coids, calcitonin, vitamin K2, active vitamin D compounds,
raloxifene, or hormone replacement therapy within
2 months; had serum calcium levels of above 10.4 mg/dL
or urinary calcium excretion of over 0.4 mg/dL GF; or had
serum creatinine above 1.3 mg/dL.
Fracture assessment
The incidence of non-traumatic new vertebral fractures was
evaluated by using lateral radiographs of the thoracic and
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lumbar spine obtained at baseline and at 6, 12, 24, and
36 months after initiation of drug administration [5]. At the
central facility, 3 experts independently assessed the
radiographs for fractures of 13 vertebral bodies from T4 to
L4. According to the method developed by Genant et al.,
prevalent vertebral fractures were semi-quantitatively
classified from Grade 0 to Grade 3, respectively named as
normal, mild, moderate, and severe [9]. Incident vertebral
fractures were diagnosed quantitatively if the anterior,
posterior, or middle vertebral height had decreased by at
least 15 % and by C4 mm in a vertebra [10] that was
assessed at baseline as Grade 0, 1, or 2. If the investigators’
assessments disagreed, the final assessment was made after
conference by all the investigators.
Assessment of QOL
Health-related quality of life (HRQOL) assessment of the
patients was carried out by using the Medical Outcomes
Study Short Form 36-item questionnaire (SF-36). SF-36
comprises 36 items, with 2–6 response options on an
ordinal scale, assessing 8 health concepts or domains:
physical functioning (PF), role limitations due to physical
health problems (RP), bodily pain (BP), general health
(GH), vitality (VT), social functioning (SF), role limita-
tions due to emotional problems (RE), and mental health
(MH) [11]. Each domain allows a score of 0–100, with a
higher score indicating better HRQOL. The assessment
was performed at baseline and at 12, 24, and 36 months,
and we analyzed the change in HRQOL scores from those
at baseline.
Statistical analysis
We classified each prevalent vertebral fracture by its
location on the spine and by the severity of the fracture
(Grade 0–3) using the safety analysis set (n = 1054). Then,
we compared the 2 treatment groups in the efficacy anal-
ysis set (eldecalcitol group: n = 526; alfacalcidol group:
n = 523) with respect to the spinal location of new ver-
tebral fractures, changes in the severity of vertebral frac-
tures, the incidence of upper (T4–T10)/lower (T11–L4)
vertebral fractures [12], and the incidence of severe ver-
tebral fractures. Here, the incidences of severe vertebral
fractures were calculated based on the number of patients
with incident vertebral fractures from normal to severe,
mild to severe, and moderate to severe fractures.
Analyses of upper/lower vertebral fracture incidences
were performed by Poisson regression with the number of
prevalent vertebral fractures at baseline as the covariate
(categories: no fracture, 1 fracture, [1 fracture). The
incidence of severe vertebral fractures was calculated by
Kaplan–Meier estimates at times when radiography was
performed. To compare eldecalcitol to alfacalcidol for the
incidence of severe vertebral fractures, stratified log-rank
tests (2-sided, 5 % significance level) were performed, and
stratified Cox regression models were used to determine
the hazard ratios and the 95 % confidence intervals, with
adjustment for the number of prevalent vertebral fractures
at baseline (categories: no fracture, 1 fracture,[1 fracture).
The changes in HRQOL scores from baseline were
evaluated by paired t tests for each group, and the inter-
group differences were evaluated by non-paired t tests.
Differences were considered to be statistically signifi-
cant if the p value was less than 0.05.
Results
Patient characteristics
There were no significant differences at baseline between
the eldecalcitol and the alfacalcidol groups with respect to
age, gender, number of patients with vitamin D supple-
mentation, prevalence of vertebral fractures, or HRQOL
scores (Table 1). Numbers of patients with prevalent ver-
tebral fractures of Grade 1, Grade 2, and Grade 3 were 111
(21.0 %), 132 (25.0 %), and 86 (16.3 %) in eldecalcitol
group, 120 (22.8 %), 102 (19.4 %), and 110 (20.9 %) in
alfacalcidol group, respectively.
Incidence of vertebral fractures
The prevalent vertebral fractures at baseline and the new
vertebral fractures during the study by spinal location are
shown in Fig. 1. At baseline there were 2 peaks, at T6–T8
and at T11–L1, in the distribution of prevalent vertebral
fractures in all patients. During the 3-year treatment new
vertebral fractures showed a single peak in the distribution
at T12–L1 in both groups. The incidence of lower vertebral
fractures was lower in the eldecalcitol group than in the
alfacalcidol group (p = 0.029) (Fig. 2).
Changes in the maximum grade of vertebral fracture
from pre-treatment grade to grade at final follow-up among
the patients with new vertebral fractures during the study
are shown in Table 2 by pre-treatment grade. In both
groups, the number of patients whose baseline fracture
grade of normal increased to a final fracture grade of mild
was similar in both the eldecalcitol and the alfacalcidol
groups, as was the number of patients whose baseline
fracture grade of normal or mild increased to a final frac-
ture grade of moderate; however, the incidence of severe
vertebral fractures seemed to be lower in the eldecalcitol
group than in the alfacalcidol group. The cumulative
incidence of severe vertebral fractures (Grade 3) over the
3 years was 3.8 % in the eldecalcitol group and 6.7 % in
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the alfacalcidol group by Kaplan–Meier estimates, showing
a significant difference between the 2 groups (hazard ratio,
0.53; 95 %CI 0.29–0.96, p = 0.036) (Fig. 3).
QOL
Assessment of HRQOL in all domains tended to be better
in the eldecalcitol group than in the alfacalcidol group
throughout the study period (Fig. 4). Eldecalcitol signifi-
cantly improved HRQOL scores in the domains of PF, RP,
BP, and VT at 12 months and in BP at 36 months com-
pared with their baseline values. On the other hand, alfa-
calcidol significantly improved PF and BP at 12 months
and BP at 36 months compared with their baseline values;
however, PF became significantly worse at 36 months.
Although no significant differences in each HRQOL scores
were observed between eldecalcitol and alfacalcidol during
the observational period, overall improvement from base-
line of HRQOL scores were clearly observed in the elde-
calcitol group.
Discussion
Vertebral fractures are the most common of all osteopo-
rotic fractures, and are linked to impaired mobility and
increased mortality [13, 14]. The current study re-evalu-




Data are means (SD)
There were no significant
differences at baseline
characteristics between the
eldecalcitol and the alfacalcidol
groups
Some of the data in this table
has been reported previously [5]
Eldecalcitol (n = 528) Alfacalcidol (n = 526)
Age (years) 72.2 (6.60) 72.1 (6.64)
Male patients [n (%)] 9 (1.70) 15 (2.85)
Patients with vitamin D supplementation [n (%)] 208 (39.4) 206 (39.2)
Number of prevalent vertebral fractures 1.18 (1.28) 1.25 (1.36)
Without fracture [n (%)] 199 (37.7) 194 (36.9)
With 1 fracture [n (%)] 156 (29.5) 160 (30.4)
With 2 or more fractures [n (%)] 173 (32.8) 172 (32.7)
Maximum grade of prevalent vertebral fracture
Grade 0 (normal) [n (%)] 199 (37.7) 194 (36.9)
Grade 1 (mild) [n (%)] 111 (21.0) 120 (22.8)
Grade 2 (moderate) [n (%)] 132 (25.0) 102 (19.4)
Grade 3 (severe) [n (%)] 86 (16.3) 110 (20.9)
HRQOL score
Physical functioning 74.4 (20.7) 75.2 (20.0)
Role-physical 74.8 (25.6) 76.5 (25.2)
Bodily pain 61.0 (24.3) 61.7 (23.6)
General health 61.2 (18.1) 61.5 (18.8)
Vitality 62.8 (20.6) 64.2 (20.5)
Social functioning 84.0 (22.1) 85.0 (19.6)
Role-emotional 78.1 (24.9) 81.8 (23.9)



















0 5 10 15 20 25
(number)b
Eldecalcitol Alfacalcidol














Fig. 1 Prevalence of vertebral
fractures at baseline (a),
incidence of vertebral fractures
during the study by spinal
location in eldecalcitol group
and alfacalcidol group (b)
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the effects of eldecalcitol on fracture prevention in com-
parison with alfacalcidol, subdividing the subjects based on
the spinal location and severity of vertebral fractures. It
was demonstrated that the incidences of lower vertebral
fractures as well as severe fractures were lower in the el-
decalcitol group than in the alfacalcidol group. Preventing
severe vertebral fractures is clinically worthwhile, since an
increase in severity of prevalent vertebral fractures
increases the risk for both new vertebral fractures and new
moderate or severe vertebral fractures [15, 16].
Several studies have investigated the impact of prevalent
or incident vertebral fractures on HRQOL and found that
they have an adverse impact on HRQOL regardless of
symptomatology [7, 14, 17]. A progressive worsening
trend in HRQOL with an increasing number of prevalent
fractures has been observed [18, 19]. HRQOL as evaluated
by SF-36 in patients with vertebral fractures at 7-year
follow-up was found to be reduced further than in the hip
fracture group in the domains of BP, VT, RE, and MH after
controlling for age, new fractures, and new co-morbid-
ity [14]. Based on these studies it was concluded that pain
and disability after vertebral fracture do not fade away
unless effective treatment is given [14, 20, 21].
Improvement of HRQOL in patients with osteoporosis
has been reported following pharmaceutical treatment with
alendronate [22, 23], risedronate [24], elcatonin [25], and
teriparatide [26]. In those studies, HRQOL improved sig-
nificantly with alendronate or risedronate treatment as
































Fig. 2 Incidence of new vertebral fractures in specific locations. The
colors of the bar indicate number of vertebral fractures present
simultaneously
Table 2 Severity of new vertebral fractures
Pre-treatment grade (A) Eldecalcitol Total (B) Alfacalcidol Total
Final fracture grade Final fracture grade
Mild Moderate Severe Mild Moderate Severe
Normal (Grade 0) 17 24 11 52 17 31 19 67
(26.6 %) (37.5 %) (17.2 %) (81.3 %) (21.3 %) (38.8 %) (23.8 %) (83.8 %)
Mild (Grade 1) – 5 0 5 – 2 2 4
– (7.8 %) (0.0 %) (7.8 %) – (2.5 %) (2.5 %) (5.0 %)
Moderate (Grade 2) – 1a 6 7 – – 9 9
– (1.6 %) (9.4 %) (10.9 %) – – (11.3 %) (11.3 %)
Total 17 30 17 64 17 33 30 80
(26.6 %) (46.9 %) (26.6 %) (100 %) (21.3 %) (41.3 %) (37.5 %) (100 %)
Data are number of patients
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Fig. 3 Incidence of new severe vertebral fractures. The incidence of
severe vertebral fractures (Grade 3) over 3 years was 3.8 % in the
eldecalcitol group and 6.7 % in the alfacalcidol group by Kaplan–
Meier estimates, showing a significant difference
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assessed HRQOL for the first time in a trial of active vita-
min D3 in Japanese patients with osteoporosis. Our results
clearly demonstrated an improvement in HRQOL after
treatment with either eldecalcitol or alfacalcidol; however,
greater improvement was observed in the eldecalcitol
group. The impact of prevalent or incident vertebral frac-
tures is dependent on the spinal location and fractures in the
lumbar region have the most severe consequences [18].
Significant differences in HRQOL between patients with
thoracic and lumbar fractures have been reported in previ-
ous studies [8, 18, 19]. In comparison to thoracic fractures,
lumbar fractures had significantly stronger impact on the
HRQOL domains of physical activity, general health per-
ception, and on total scores [18]. This difference occurs
because lumbar fractures are more often symptomatic than
thoracic fractures, due to stabilization of the thoracic spine
by the rib cage. It was reported that for patients with ver-
tebral fractures without symptoms, changes in HRQOL
score were intermediate between those for patients with
symptomatic vertebral fractures and those for patients
without incident vertebral fractures [18]. The improvement
in HRQOL achieved in this study by eldecalcitol is partially
owing to the higher preventive effects of eldecalcitol on
vertebral fractures especially in the lower part of the spine
(T11–L4). This also explains why bodily pain was
improved most among the SF-36 domains during the
observational period. Because lumbar kyphosis is thought
to be related to weakness of the spinal extensors, whole
kyphosis usually forces the patient to use a cane while
standing and walking, resulting in a significant reduction in
HRQOL compared with other postural deformities [8].
This study has several limitations. Firstly, the present
study lacked a placebo group. The protocol was planned
without a placebo group from the ethical point of view.
Secondly, we evaluated incident vertebral fractures by
morphometric assessment, and included both symptomatic
and asymptomatic patients. This might have affected the
HRQOL scores; however, since baseline characteristics for
both groups showed no difference, its influence is limited
and would not affect the results.
In conclusion, the incidences of lower spinal vertebral
fractures and severe vertebral fractures were reduced fur-
ther by eldecalcitol compared to alfacalcidol in the 3-year
phase III clinical trial. Daily treatment with 0.75 lg elde-
calcitol for 3 years is effective in improving HRQOL,
possibly owing to the reduced risk of lower spinal vertebral
fractures or severe vertebral fractures.
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Fig. 4 Changes from baseline in HRQOL scores as evaluated by SF-
36. *Significantly different from baseline (p \ 0.05). PF physical
functioning, RP role limitations due to physical health problems, BP
bodily pain, GH general health, VT vitality, SF social functioning, RE
role limitations due to emotional problems, MH mental health
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